➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Colorcon
Boehringer Ingelheim
Johnson and Johnson

Last Updated: July 24, 2021

DrugPatentWatch Database Preview

Fremanezumab-vfrm - Biologic Drug Details


Email this page to a colleague

« Back to Dashboard

Summary for fremanezumab-vfrm
Recent Litigation for fremanezumab-vfrm

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company2018-09-27

See all fremanezumab-vfrm litigation

PTAB Litigation
PetitionerDate
Eli Lilly and Company2018-09-28

See all fremanezumab-vfrm litigation

Company Disclosures: US Patents for fremanezumab-vfrm

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Teva Pharms Usa AJOVY fremanezumab-vfrm INJECTABLE;INJECTION 761089 001 2018-09-14 ⤷  Free Forever Trial Rinat Neuroscience Corporation (South San Francisco, CA) 2025-11-14 RX company
Teva Pharms Usa AJOVY fremanezumab-vfrm INJECTABLE;INJECTION 761089 001 2018-09-14 ⤷  Free Forever Trial Labrys Biologics, Inc. (San Mateo, CA) 2025-11-14 RX company
Teva Pharms Usa AJOVY fremanezumab-vfrm INJECTABLE;INJECTION 761089 001 2018-09-14 ⤷  Free Forever Trial Teva Pharmaceuticals International GmbH (Jona, CH) 2034-03-21 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for fremanezumab-vfrm

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
19/040 Ireland ⤷  Free Forever Trial PRODUCT NAME: FREMANEZUMAB; NAT AUTHORISATION NO/DATE: EU/1/19/1358 20190328
C00119 Luxembourg ⤷  Free Forever Trial PRODUCT NAME: GALCANEZUMAB; AUTHORISATION NUMBER AND DATE: EU/1/18/1330 20181116
2019000072 Germany ⤷  Free Forever Trial PRODUCT NAME: FREMANEZUMAB; REGISTRATION NO/DATE: EU/1/19/1358 20190328
0190022 00278 Estonia ⤷  Free Forever Trial PRODUCT NAME: GALKANEZUMAB;REG NO/DATE: EU/1/18/1330 16.11.2018
01930047 Spain ⤷  Free Forever Trial PRODUCT NAME: FREMANEZUMAB; NATIONAL AUTHORISATION NUMBER: EU/1/19/1358; DATE OF AUTHORISATION: 20190328; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1358; DATE OF FIRST AUTHORISATION IN EEA: 20190328
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Merck
Dow
Moodys
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.